Table 2.

Summary of Phase I trials designed to evaluate the tolerability and safety of ixabepilone in combination with chemotherapy in the management of solid tumors refractory to standard therapies, including pancreatic cancer^*

Reference	Patients enrolled (n)	Chemotherapeutic agent pairing	Ixabepilone MTD	Reported survival
Faivre et al26	43 (41 were actually treated)	Irinotecan 180 mg/m2 every 14 days	Intravenous 20 mg/m2 every 14 days	Five of 41 treated patients demonstrated objective responses
Plummer et al27	55 (52 were actually treated)	Carboplatin AUC of 6, day 1	Intravenous 30 mg/m2, day 1 or 20 mg/m2, days 1 and 8 both on a 21-day cycle	Six of 52 treated patients demonstrated partial responses

Note:

^*Survival data, reported as secondary objectives in these studies, are also summarized in this table.

Abbreviations: AUC, area under the concentration-time curve; MTD, maximum tolerated dose.